Innovation Tracking Factbook 2018: An Assessment of the Pharmaceutical Pipeline - Innovation is Moving Towards Biologics, Small Molecules are Still Favored by the Pharmaceutical Industry
DUBLIN, Jan. 22, 2019 /PRNewswire/ --
The "Innovation Tracking Factbook 2018: An Assessment of the Pharmaceutical Pipeline" report has been added to ResearchAndMarkets.com's offering.
Cost of developing new drug molecules continues to increase
The cost of developing a new drug molecule has reached a record level and shows no sign of decreasing in the near future. Adding to this burden, most of the drugs fail to recuperate the R&D cost after entering the market, building huge pressure on the pharmaceutical industry to reduce the cost. Competition from generics and me-too products are also showing their presence, and the effect of generic substitution has increased in recent years.
One of the methods companies use to gain more revenue is developing first-in-class products. Though developing first-in-class products requires high investment in terms of time and money, it has proven to result in blockbuster drugs,
when compared with me-too products.
Over recent decades, in addition to an increase in the yearly number of new chemical entity approvals by the FDA, the number and proportion of these approvals that were first-in-class at the time of approval have also increased. The proportion of first-in-class approvals has increased steadily each year since 2002 and is helping to meet the unmet needs.
Advancements in the fields of genetics, genomics, metabolomics and cell biology at the molecular level over the past two decades have deepened the available knowledge about different diseases and their underlying mechanisms paving the way to find more targets and bring target-oriented drug deliveries into the market.
A greater diversity in terms of the molecular targets in successfully approved products and pipeline development programs has been achieved in many of the most prevalent indications in these areas, thereby increasing the chances of the emergence of therapeutics that could transform the clinical and commercial landscape.
Although innovation is moving towards biologics, small molecules are still favored by the pharmaceutical industry
Small molecule products are leading the pipeline owing to their inherent nature of action and the cost of developing them. Small molecules have also proven their worth in generating revenue and are ranked top in terms of sales. Combination and multiple therapies are also a strategy to bring new drugs into market and maximize the return on investment. Currently oncology holds the highest number of multiple therapy drugs.
Key Topics Covered:
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Increasing Cost of Drug Development
2.2 Most Drugs Fail to Recuperate R&D Costs
2.3 Contracting Life Cycles for Approved Products
2.4 The Case for First-in-Class Pharmaceutical Innovation
2.5 Status of Innovation in Rare Diseases
2.6 Conclusion
3 Assessment of Pharmaceutical Industry Pipeline
3.1 Pipeline and Clinical Trials Landscape by Therapy Area
3.2 Pipeline by Stage of Development
3.3 Pipeline by Molecule Type
3.4 Key Therapy Areas by Indication
3.4.1 Oncology
3.4.2 Infectious Diseases
3.4.3 Central Nervous System
3.4.4 Immunology
3.5 Conclusion
4 Assessment of Innovation in the Pharmaceutical Industry Pipeline
4.1 First-in-Class Innovation by Stage of Development
4.2 Key Therapy Areas by Indication
4.2.1 Oncology
4.2.2 Infectious Diseases
4.2.3 Central Nervous System
4.2.4 Immunology
4.3 Conclusion
5 Appendix
For more information about this report visit https://www.researchandmarkets.com/research/38nq7l/innovation?w=5
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
Media Contact:
Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets
Share this article